BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Innovations | Feb 13, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on PAD4 could help predict the risk of ALS. Genome-wide association studies in 1,955 ALS patients and 28,244 unaffected individuals identified an associations between a SNP on PAD4, SNP (rs2240335), and...
BC Innovations | Apr 7, 2016
Distillery Therapeutics

Therapeutics: Peptidyl arginine deiminase type IV (PAD4; PADI4)

Gastrointestinal disease INDICATION: Pancreatitis Mouse studies suggest inhibiting PAD4 could help treat pancreatitis. In a mouse model of inflammatory ductal occlusion pancreatitis, PAD4 knockout decreased fibro-inflammatory remodeling, mesenchymal expansion and other markers of pancreatitis compared...
BC Innovations | Jul 9, 2015
Product R&D

Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity....
BC Innovations | Apr 30, 2015
Strategy

Padlock's keys to academia

Padlock Therapeutics Inc. isn't using its $23 million from a recent series A round to build research in-house or through a network of CROs. Instead, it's turning to academia to build the biology around its...
BC Innovations | Mar 12, 2015
Distillery Therapeutics

Therapeutics: Peptidyl arginine deiminase (PADI; PAD); PADI type IV (PADI4, PAD4)

Autoimmune disease INDICATION: Autoimmune; cancer In vitro studies have identified PADI inhibitors that could help treat autoimmune diseases and cancer. A chemical screen identified multiple chloro-amidine analogs that inhibited PADI4 and three other PADIs. In...
BC Innovations | Feb 19, 2015
Distillery Therapeutics

Therapeutics: Peptidyl arginine deiminase type IV (PADI4; PAD4)

Autoimmune disease INDICATION: Autoimmune; cardiovascular In vitro studies have identified selective, reversible PADI4 inhibitors that could be help treat various autoimmune and cardiovascular diseases. In vitro assays identified two PADI4 inhibitors that selectively and reversibly...
BioCentury | Jan 19, 2015
Emerging Company Profile

Unlocking PADs

Padlock Therapeutics Inc. is developing a pipeline of small molecule inhibitors of PAD enzymes to prevent the production of autoantigens that can trigger autoimmune diseases. The approach could selectively treat and potentially even prevent diseases...
BC Innovations | Jun 20, 2013
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Peptidyl arginine deiminase type III (PADI3; PAD3) autoantibodies as a prognostic marker for rheumatoid arthritis (RA) Patient sample studies suggest autoantibodies that recognize PAD3 and activate...
BC Innovations | May 30, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis Peptidyl arginine deiminase type IV (PADI4; PAD4) Mouse studies suggest PAD4 inhibition could help treat or prevent thrombosis. PAD4...
Items per page:
1 - 10 of 12